secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-063134
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus receives Nasdaq delisting notice for equity below $2.5M minimum
----------------------------------------------------------------------

- Nasdaq notified Corbus on Nov 10, 2023 that stockholders' equity of $311,016 as of Sept 30, 2023 is below the $2.5M minimum for continued listing.
- Corbus has 45 calendar days, until Dec 26, 2023, to submit a plan to regain compliance with Listing Rule 5550(b)(1).
- If Nasdaq accepts the plan, it may grant an extension up to May 8, 2024; rejection can be appealed to a hearings panel.
- Company also updated risk factors to warn of potential delisting consequences: reduced liquidity, penny stock rules, and impaired capital raising ability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023063134/0000950170-23-063134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023063134/crbp-20231110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer